Treatment With Namenda in Women at Risk for Cognitive Decline
Trial ID or NCT#
This research aims to explore the effectiveness of memantine (Namenda) in treating post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline. Memantine has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
Cognitive Effects of Memantine in Postmenopausal Women at Risk of Dementia: a Pilot Study
- : - Women between the ages of 50-65 - Willing to sign Human Subjects Protection Consent Form - Personal or family history of mood disorder - Hypothyroidism - Diabetes - Family history of Alzheimer's disease
- - Possible or probable Alzheimer's disease or dementia - History of cerebrovascular disease - History of myocardial infarction within the previous year - History of unstable heart disease - Uncontrolled hypertension - Less than 8 years of education - English as a 2nd language - Uncorrected vision or hearing deficits